Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor. (October 2020) - Kizilbash, S.H.; El-Khoueiry, A.; Lerner, R.E.; Ma, P.C.; Almubarak, M.; Mody, K.; Burkard, M.E.; Guarino, M.; Jenab-Wolcott, J.; Sankar, N.; Choy, G.; Espiritu, L.; et al.